BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 15460213)

  • 1. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
    Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
    Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".
    Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
    Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():23-9. PubMed ID: 15353899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
    Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
    Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study.
    Friedel WE; Matthes H; Bock PR; Zänker KS
    J Soc Integr Oncol; 2009; 7(4):137-45. PubMed ID: 19883529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study.
    Schumacher K; Schneider B; Reich G; Stiefel T; Stoll G; Bock PR; Hanisch J; Beuth J
    Anticancer Res; 2003; 23(6D):5081-7. PubMed ID: 14981970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology.
    Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
    Integr Cancer Ther; 2015 Mar; 14(2):140-8. PubMed ID: 25552476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador).
    Grossarth-Maticek R; Ziegler R
    Eur J Med Res; 2008 Mar; 13(3):107-20. PubMed ID: 18499556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract.
    Elsässer-Beile U; Leiber C; Wolf P; Lucht M; Mengs U; Wetterauer U
    J Urol; 2005 Jul; 174(1):76-9. PubMed ID: 15947582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case reports of sarcoma patients with optimized lectin-oriented mistletoe extract therapy.
    Kirsch A; Hajto T
    J Altern Complement Med; 2011 Oct; 17(10):973-9. PubMed ID: 22010781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador).
    Grossarth-Maticek R; Ziegler R
    Forsch Komplementmed; 2006 Oct; 13(5):285-92. PubMed ID: 17057389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study.
    Grossarth-Maticek R; Kiene H; Baumgartner SM; Ziegler R
    Altern Ther Health Med; 2001; 7(3):57-66, 68-72, 74-6 passim. PubMed ID: 11347286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer.
    Elsässer-Beile U; Leiber C; Wetterauer U; Bühler P; Wolf P; Lucht M; Mengs U
    Anticancer Res; 2005; 25(6C):4733-6. PubMed ID: 16334168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador.
    Grossarth-Maticek R; Ziegler R
    Arzneimittelforschung; 2007; 57(10):665-78. PubMed ID: 18074761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis.
    Grossarth-Maticek R; Ziegler R
    Eur J Med Res; 2006 Nov; 11(11):485-95. PubMed ID: 17182361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients.
    Schad F; Thronicke A; Merkle A; Matthes H; Steele ML
    Phytomedicine; 2017 Dec; 36():54-58. PubMed ID: 29157828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
    Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
    Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract.
    Eisenbraun J; Scheer R; Kröz M; Schad F; Huber R
    Phytomedicine; 2011 Jan; 18(2-3):151-7. PubMed ID: 20724129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complementary Treatment with Mistletoe Extracts During Chemotherapy: Safety, Neutropenia, Fever, and Quality of Life Assessed in a Randomized Study.
    Pelzer F; Tröger W; Nat DR
    J Altern Complement Med; 2018; 24(9-10):954-961. PubMed ID: 30247950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.